Affimed NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AFMD Nasdaq 8731 https://www.affimed.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Affimed NV

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - Jun 10th, 2022 2:31 pm
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates - Jun 1st, 2022 11:55 am
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress - Jun 1st, 2022 10:30 am
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO) - May 26th, 2022 9:05 pm
Affimed to Present at the 2022 Jefferies Healthcare Conference - May 26th, 2022 10:30 am
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - May 25th, 2022 7:00 pm
Affimed Announces Annual General Meeting of Shareholders - May 24th, 2022 10:30 am
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022 - May 24th, 2022 10:30 am
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity - May 16th, 2022 12:00 pm
What Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own? - May 14th, 2022 12:06 pm
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - May 12th, 2022 2:31 pm
Affimed Provides Update on ASCO AFM13-104 Oral Presentation - May 6th, 2022 8:02 pm
CORRECTING and REPLACING -- Affimed N.V. - Apr 27th, 2022 9:21 pm
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO) - Apr 27th, 2022 8:05 pm
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Apr 18th, 2022 3:28 pm
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - Apr 13th, 2022 2:02 am
Affimed Announces Proposed Public Offering of Common Shares - Apr 12th, 2022 8:03 pm
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings - Apr 11th, 2022 7:59 pm
Why Affimed Stock Is Heating Up Today - Apr 11th, 2022 4:22 pm
SVB Leerink: Affimed's data for experimental Hodgkin's therapy is 'validating' - Apr 11th, 2022 12:09 pm